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Abstract
Amelogenin is an extracellular protein first identified as a matrix component important for formation of dental enamel
during tooth development. Lately, amelogenin has also been found to have positive effects on clinical important areas, such
as treatment of periodontal defects, wound healing, and bone regeneration. Here we present a simple method for
purification of recombinant human amelogenin expressed in Escherichia coli, based on the solubility properties of
amelogenin. The method combines cell lysis with recovery/purification of the protein and generates a .95% pure
amelogenin in one step using intact harvested cells as starting material. By using amelogenin as a fusion partner we could
further demonstrate that the same method also be can explored to purify other target proteins/peptides in an effective
manner. For instance, a fusion between the clinically used protein PTH (parathyroid hormone) and amelogenin was
successfully expressed and purified, and the amelogenin part could be removed from PTH by using a site-specific protease.
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Introduction
Enamel is the hardest tissue in the vertebrate body and is made
up from highly arranged hydroxyapatite crystals. During enamel
formation the enamel matrix is secreted from special epithelial
cells called ameloblasts and around 90% of the organic content of
the developing enamel matrix is comprised of the extracellular
protein amelogenin. The suggested function of amelogenin in
enamel formation is to direct the growth of the hydroxyapatite
crystals, which are highly elongated along the c-axis [1–3]. In the
enamel matrix amelogenin is proteolytically processed by matrix
metalloproteinase-20 and kallikrein-4, which together with
alternative splicing of amelogenin transcripts creates a complex
mixture of amelogenin poly peptides. As the enamel matures
amelogenin is removed from the matrix by proteolytic degrada-
tion, and mature enamel is almost completely inorganic [4]. Much
depending on the complexity of the enamel matrix the exact
mechanism of amelogenin during enamel formation remains to be
revealed.
Lately amelogenin has been detected also in non-dental tissue,
such as brain and the hematopoietic system [5]. In vitro and in vivo
experiments have shown that amelogenin, apart from acting as a
structural protein in biomineralization, also appears to have signal
molecule like properties [6–7]. Porcine enamel matrix derivate
(EMD), containing extracted amelogenins, have been found to
regenerate periodontal tissues like periodontal ligament (PDL),
cementum and alveolar bone [8], and is used clinically in dentistry
to treat periodontal defects [9], and also in the treatment of leg
ulcers [10]. A positive effect on bone regeneration has also been
seen in rat femur and skull [11–12], and amelogenin has been
reported to have positive effects on angiogenesis and wound
healing in animal models [10,13–15]. So far the clinical
applications of amelogenin are limited to treatment of periodontal
defects and leg ulcers, but increased clinical use may be expected
in the future [16]. To explain the apparent regenerative effect of
amelogenin it has been proposed that amelogenin may have
several different functions and that certain splicing variants have
distinct effects on different cell types. Amelogenin seems to
enhance the proliferation of PDL cells [17–18], regulate genes
associated with cementoblasts [19–20], and have been found to
induce chondrogenic and osteogenic phenotype in embryonic
muscle fibroblasts [21]. Apart from use as a therapeutic,
amelogenin has also been proposed to promote creation of new
biomaterials, such as coatings on titanium implants, giving further
applications to amelogenin proteins [22].
Amelogenin has the ability to form supramolecular aggregates
(termed nanospheres) [23], and this property appears to be
important for the biological activity during enamel formation
[24]. Mutations in amelogenin, found in the disease Amelogenesis
imperfect, causing deformed enamel, have been found to affect
amelogenin aggregation properties such as nanosphere size in vitro
[25–27]. This implies a close connection between nanosphere
formation and biologic activity of amelogenin. Larger amelogenin
assemblies, as a result of further aggregation of amelogenin
nanospheres, have also been reported [28–29]. The aggregation
behavior of amelogenin is related to its characteristic solubility
properties, with the best solubility observed in the acidic area, low
solubility at physiological pH, followed by a higher solubility in the
basic area [30–31].
Recombinant amelogenin produced in Escherichia coli was first
described by Simmer et al. [30], using the most common splicing
variant of murine amelogenin. The described method for isolation
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subsequent reports, comprises: cell disruption by sonication under
denaturating conditions (6 M guanidine hydrochloride), centrifu-
gation, repeated ammonium sulphate precipitations, centrifuga-
tion, followed by reversed phase (C4) chromatography. The
purified protein is obtained in aqueous acetonitrile at a reported
yield of 4–11 mg/ liter cell culture. Expression levels of
recombinant amelogenin can be improved in E. coli by using an
N-terminal histidine tag [32].
The aim of this study was to find a method of isolating untagged
recombinant amelogenin without using acetonitrile or chaotropic
agents, preferably feasible to do in a large scale. We managed to
utilize the solubility properties of amelogenin to efficiently separate
recombinant human amelogenin from host cell proteins in a one-
step procedure using intact E. coli cells. A procedure to use the
same method for purifying other recombinant proteins/peptides is
demonstrated.
Results
Creating an amelogenin expression vector
For expression of recombinant amelogenin a synthetic gene
encoding the most common splicing variant of human amelogenin
(Swissprot Q99217, isoform 1, excluding the signal peptide), codon
optimized for E. coli, was successfully created. Amelogenin was
expressed from a pET11 plasmid vector (Novagen) in E. coli BL21
(DE3) cells after cultivation in shake flasks and high levels of
amelogenin could be observed when total cell proteins were
analyzed by SDS-PAGE (Figure 1).
Amelogenin purification
After cultivation the amelogenin expressing cells were harvested
by centrifugation. Cell disruption by sonication in solutions with
different pH generated different amounts of soluble amelogenin in
the cleared cell lysates. Sonication in buffers with physiological pH
resulted in a low concentration of soluble amelogenin, but this
could be improved by lowering the pH. The presence of
contaminating host cell proteins in the cleared lysates was also
affected by the pH in the sonication buffer, with higher amounts
present at physiological pH. Sonication of the amelogenin
expressing cells in 3% acetic acid yielded a soluble amelogenin,
and at the same time also precipitated the major fraction of E. coli
proteins (Figure 1, lane).
To test the stability of amelogenin in the cleared lysate obtained
after sonication in 3% HAc the lysate was subjected to heat
treatments at 60 or 80uC. Analysis of the soluble fractions after the
heat treatment showed that amelogenin was still soluble after
20 minutes at 80uC. No reduction in soluble amelogenin
concentration or other negative effects of the heat treatment
could be observed.
Since sonication is not very feasible in large scale, disruption of
intact amelogenin expressing cells using heat treatment was tested.
Intact harvested cells suspended in 3% HAc were heat treated at
80uC for 20 minutes, without prior treatment. Cell debris and
precipitated proteins were removed by centrifugation, and the
soluble fraction was analyzed by SDS-PAGE. This treatment
generated an amelogenin solution with very low amounts of host
cell proteins. The purity of the amelogenin was higher when only
heat treatment was used for cell lysis/purification, compared to
when sonication was used, alone or in combination with heat
treatment (Figure 1). Control experiments with cells harboring
empty pET11 vector were performed and showed very low
amount of soluble proteins after treatment at low pH and high
temperature.
Variations in the acid/heat treatment purification procedure
can be made and still obtaining comparable results. HAc
concentrations between 0.5 and 5% were successfully tested,
showing an increase in yield at the higher concentrations, but a
slightly lower purity. The volume of HAc used was successfully
tested between 60 and 600 ml for cells from one liter of cultivation
(21 g wet weight cells), with the total yield increasing with
increasing volume HAc (data not showed).
Characterization of purified amelogenin
SDS-PAGE and reversed phase high-performance liquid
chromatography (HPLC) analysis both showed a very high purity
(.95%) of amelogenin purified only with the acid/heat treatment
method (Figure 1 and 2a). A yield of up to ,1 g/liter shake flask
culture could be obtained after a single acid/heat treatment step.
MALDI-TOF mass spectrometry analysis (Figure 2b) showed a
molecular mass within 2 Da from the expected theoretical mass of
the purified amelogenin (19804.8 Da) and Western blot analysis
with anti amelogenin antibodies was positive (Figure 2c), confirm-
ing the identity of the purified protein.
Amelogenin purified with the acid/heat treatment method was
also subjected to a pH solubility test (Figure 2d) and was found to
be largely insoluble at pH 6–7.5 and soluble at more acidic or
basic pH.
To verify that the purification procedure not had affected the
aggregation properties of amelogenin the size of the amelogenin
aggregates was measured using dynamic light scattering (DLS).
The purified amelogenin formed nanospheres with a hydrody-
namic radius (RH) of 19.664.5 nm at pH 8.0.
Amelogenin as purification tag
Recombinant amelogenin could be efficiently separated from E.
coli proteins by a simple heat treatment of the intact cells in 3%
HAc. The ease of the process makes it attractive to test also for
Figure 1. SDS-PAGE analysis of samples from different stages
of purification of recombinant amelogenin from E. coli cells.
Lanes marked with (A) represent samples from cells expressing
amelogenin and lanes marked with (N) refers to negative control cells
harboring empty expression vector. Lanes marked with (1) represent
whole cell samples after cultivation. Lanes marked (2), (3) and (4)
represent samples after different treatments of the intact cells. (2):
soluble fractions of cells sonication in 3% HAc. (3): soluble fractions after
heat treatment of the sonicated samples in lanes 2A and 2N. (4): soluble
fractions of cells directly heat treated at 80uC. This generates the most
pure amelogenin. Lanes marked (M) contain molecular weight markers.
doi:10.1371/journal.pone.0033269.g001
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33269Figure 2. Characterization of recombinant human amelogenin purified using an acid/heat treatment method. A) C18 reverse phase
HPLC analysis of amelogenin purified with the acid/heat treatment method. Amelogenin elutes at ,45% acetonitrile and the peak area indicates a
purity of .95%. B) MALDI-TOF mass spectra of purified amelogenin recorded in linear mode. The obtained mass is very close from expected
theoretical mass (19804.8 Da). The peaks seen with slightly higher masses than the main peak is most likely satellite signals derived from matrix
adducts that have reacted with the polypeptide. C) Western blot of amelogenin samples (A) and negative controls (N). Lanes marked 1 are samples
taken from cultivated cells, and lanes marked 2 are from samples after the acid/heat treatment. Lanes marked M contain molecular weight markers.
The amelogenin containing samples show a positive reaction not seen in the negative controls, confirming the identity of the protein. The band
visible at higher molecular weights in lane 1A suggests that a multimeric form of amelogenin is present inside the cells. D) SDS-PAGE analysis of
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tion, with low pH and high temperature, may be too harsh for
many proteins. Therefore, a fusion protein approach was tested to
see if amelogenin could facilitate purification of other target
proteins/peptides using the acid/heat treatment method.
Human parathyroid hormone (PTH), used clinically to treat
osteoporosis [33], was used as a model to verify our method. The
gene encoding the active part of PTH (PTH1–34) was fused
downstream of the amelogenin gene to generate an amelogenin-
PTH fusion protein (Figure 3a). Amelogenin and PTH were
separated with a glycine-serine linker and an enterokinase cleavage
site, allowing for site-specific proteolytic removal of amelogenin.
Production of the fusion protein was carried out in the same way
as for amelogenin and it was expressed at high levels in E. coli
BL21 (DE3) cells. The fusion protein could be purified using the
acid/heat treatment method, with a similar yield and purity as for
amelogenin. In order to disconnect PTH from amelogenin the
fusion protein was treated with enterokinase at pH 4.5, which
completely cleaved the fusion protein into free amelogenin and
PTH. After the cleavage most of the amelogenin could be
precipitated from the reaction mixture by raising the pH to ,7
using NaOH, or by adding NaCl to a concentration of $150 mM
at pH 4.5. The precipitated amelogenin could then be separated
from the soluble PTH by centrifugation (Figure 3b). A plasmid
vector containing PTH alone was prepared as a control, but no
PTH could be detected in whole cell samples or in the purified
samples.
Several other amelogenin fusion proteins have also been
successfully produced with the acid/heat treatment method, for
instance an amelogenin-ameloblastin fusion protein.
Discussion
In this report we have described a method for purification of
recombinant human amelogenin, by utilizing the special solubility
properties of amelogenin. We have also showed that the same
method can be used to purify an amelogenin fusion protein
(amelogenin-PTH), suggesting that amelogenin can be used as a
purification tag for production of other recombinant proteins or
peptides.
The described method comprises heat treatment at 80uCo f
intact amelogenin producing E. coli cells suspended in 3% HAc,
followed by isolation of the soluble fraction. The number of steps is
kept to a minimum and everything from harvesting of the cells to
isolation of the purified amelogenin can be carried out in the same
vessel. The method should be well suited also for large-scale
applications and involves minimal use of chemicals or expensive
materials. The thermal lysis used could have several advantages for
process scale use, such as product sterilization, protease inactiva-
tion and generation of relatively large cell debris which may be
more easily separated from the soluble fraction [34]. Some
amelogenin was released from the cells even without heat
treatment, indicating that some cell disruption occur only as a
result of the acidic environment. The method should be seen as a
combined cell disruption and product capture/purification step
and additional purification steps, e.g. chromatographic techniques,
may be necessary depending on the application of the protein.
Nevertheless, the described method should be an excellent first
step regardless of the application of the final product and is
compatible with subsequent purification techniques.
The effect of the purification procedure on the biologic activity
of recombinant amelogenin can not be easily assayed since
amelogenin lacks suitable measurable activity. However, when our
amelogenin preparation was proteolytically digested, it exhibited
similar growth stimulating effects on cell cultures as murine
amelogenin. Previously, a preparation containing porcine amelo-
genin (EMD), extensively used in the literature, was also reported
withstanding high temperatures without precipitating [35] or
losing the bioactivities [36]. The solubility profile and the
aggregation properties of the human amelogenin tested in this
study is also in line with what has been previously reported for
recombinant murine amelogenin [30–31,37]. This shows that
amelogenin purified in this work share the same physiochemical
characteristics as amelogenin in previous reports purified using the
original method by Simmer et al. [30], and is not negatively
affected by purification procedures.
The measured mass of the purified amelogenin suggests that the
N-terminal methionine is missing in the purified protein, a
phenomenon previously reported and suggested to be caused by E.
coli methionine aminopeptidase [30]. The apparent molecular
mass derived from the SDS-PAGE gel is higher than the mass
measured with MALDI-TOF mass spectrometry. This slow
migration of amelogenin on SDS-PAGE gels have been previously
reported and is possibly due to the unusual primary sequence of
amelogenin [30].
amelogenin solubility test, showing the soluble fractions of purified amelogenin at pH 2–10. The protein is only sparingly soluble at pH 6–7.5, but is
readily soluble at more acidic or basic pH.
doi:10.1371/journal.pone.0033269.g002
Figure 3. A) Schematic structure of the amelogenin-PTH fusion
protein. The amelogenin (in the N-terminal) and PTH (in the C-terminal)
are separated by a glycine-serine linker (L) and an enterokinase site (EK).
The arrow indicates the cleavage point of enterokinase. B) SDS-PAGE
gel for analysis of amelogenin-PTH cleavage with enterokinase. Lane 1
is amelogenin purified with acid/heat treatment method and lanes 2–7
are purified amelogenin-PTH at different time points during enteroki-
nase cleavage: 0 h, 1 h, 2 h, 4 h, 8 h and 24 h. Lanes 8–10 are samples
after 4 h, 8 h and 24 h of cleavage where the amelogenin and
amelogenin-PTH have been removed by precipitation at pH 7. Lanes
11–13 are also samples after 4 h, 8 h and 24 h of cleavage, but here the
amelogenin and amelogenin-PTH have been removed by precipitation
using 250 mM NaCl. Lanes marked M contain molecular weight marker.
PTH is indicated with an arrow.
doi:10.1371/journal.pone.0033269.g003
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separating recombinant amelogenin from E. coli proteins. This
suggests that amelogenin could be used as a purification tag to
facilitate purification of other proteins or peptides using the same
method. Indeed, an amelogenin-PTH fusion protein was success-
fully separated from host cell proteins, and isolation of the target
protein (PTH) could be carried out by digesting the fusion protein
with a site specific protease followed by precipitation of the
amelogenin part by adjusting the pH to ,7 or by increasing the
salt concentration.
The solubility of the amelogenin-PTH fusion protein showed a
similar profile to that of amelogenin, with a low solubility at
physiologic pH (data not shown). This may restrict the choice of
method for removal of the amelogenin purification tag, since the
fusion protein needs to be soluble to do this. In this work
enterokinase was used for specific proteolytic tag removal, since it
is active at acidic pH, which circumvents the potential solubility
problem.
The results presented here describe a novel method for
amelogenin purification, and identify amelogenin as an attractive
fusion partner as a carrier protein for other target proteins/
peptides. In one step intact host cells are treated to produce a
.95% pure amelogenin, with minimal use of chemicals, and the
same procedure can also be used to purify amelogenin fusion
proteins to a similar purity. This implies that amelogenin not only
has use as a therapeutic agent, but also can be used to facilitate
production of other important peptides and proteins.
Materials and Methods
Gene synthesis
A gene encoding the X-chromosomal human 175 amino acid
amelogenin (Swissprot Q99217, isoform 1, excluding the signal
peptide) was synthesized by polymerase chain reaction (PCR).
Nine oligonucleotides ,80 bp long with ,20 bp complementary
ends were used to build the gene, which was codon optimized for
E. coli. The oligonucleotides (0.05 mM of each oligonucleotide in
the reaction mixture) were mixed and assembled using PfuUltra
Hotstart DNA polymerase (Stratagene). The assembled amelo-
genin gene was amplified, by using flanking primers and the
assembly mixture as template, and subsequently cloned into a
cloning vector. The gene was sequenced and point mutations were
corrected with QuickChange Site-Directed Mutagenesis Kit
(Stratagene). The gene was finally inserted between the NdeI and
BamHI sites in the expression vector pET11a (Novagen). For the
gene encoding human PTH1-34 two ,80 bp oligonucleotides
were used and the gene assembly, amplification and cloning
procedures were the same as for amelogenin.
Construction of amelogenin-PTH fusion protein
The genes encoding amelogenin and PTH were individually
amplified by PCR. The primers were designed to add extra
complementary sequence downstream of the amelogenin gene and
upstream of the PTH gene. The complementary sequence
encoded a glycine-serine linker and an enterokinase site (Asp-
Asp-Asp-Asp-Lys). The two genes could be assembled, utilizing the
complementary sequence, and subsequently amplified with
flanking primers using PfuUltra Hotstart DNA polymerase. The
amelogenin-PTH gene was subsequently cloned into a pET11
expression vector the NdeI and BamHI sites.
Cultivation
All cultivation was carried out in shake flasks using the E. coli
expression strain BL21 (DE3), transformed with the proper
expression vector. The cultivations were carried out at 37uCi na
shaking incubator using TB-medium (tryptone 12 g/l, yeast
extract: 24 g/l, glycerol: 4 ml/l, 17 mM KH2PO4,7 2 m M
K2HPO4) containing 200 mg/ml ampicillin. To inoculate 100 ml
TB-medium 0.5–1 ml overnight culture was used and the
cultivations were induced with 5 mM lactose 4 hours post
inoculum. Sampling for SDS-PAGE was carried out by measuring
OD600, pellet 250 ml cell culture by centrifugation, and resuspend-
ing (and boil) the cells in SDS-PAGE loading buffer to a cell
density equivalent to an OD600 of 10.
Acid/heat treatment purification
Cells cultivated for a total of 24 hours were harvested by
centrifugation and washed in 150 mM NaCl to remove growth
medium components. The cell pellets were then resuspended in
3% acetic acid (30 ml HAc to cells from 100 ml cell culture). The
cell suspension was then subjected to sonication (8610 seconds), or
to 20 minutes heat treatment at 60 or 80uC in a water bath,
followed by centrifugation at 20 000 g for 20 minutes. The
supernatant from the sonicated sample was also heat treated and
re-centrifuged as above. All supernatants were collected and
analyzed. The samples were kept at 4–8uC during all steps except
for the heat treatment. The heat treatment of the cells at 80uC was
repeated, in new experiments, using different concentrations of
HAc (0.5–5%). Different volumes of 3% HAc were also tested (6–
60 ml to cells from 100 ml cultivation). The protein concentration
in the supernatants was measured using Bio-Rad Protein Assay
(Bio-Rad).
SDS-PAGE and Western blot
SDS-PAGE analysis was carried out on 10–20% gradient gels
stained with Coomassie brilliant blue. For Western blot a 15% gel was
electroblotted to a nitrocellulose membrane which was subsequently
blocked with 3% nonfat milk powder. The membrane was incubated
with a primary antibody against recombinant human amelogenin
(kindly supplied Straumann Biologics, Malmo ¨, Sweden) and then with
a secondary horse radish peroxidase conjugated antibody. The
membrane was developed with HRP Color Development Reagent
(Bio-Rad).
Solubility test
Amelogenin purified with the acid/heat treatment method was
dialyzed against 0.05% acetic acid adjusted to pH 4 with NaOH,
and concentrated ,10 times using Vivaspin 6 ultrafiltration
membrane (Sartorius). Five ml of the concentrated sample was
mixed with 95 ml of 0.1 M buffers with pH ranging from 2 to 10.
The samples were then incubated 1 hour at room temperature
and centrifuged 15 minutes as 16 000 g. The supernatant
containing the soluble fraction was analyzed by SDS-PAGE.
Dynamic light scattering
Amelogenin samples (5 mg/ml in 100 mM glycine, pH 8.0),
were analyzed at 20uC using a DynaPro instrument from
ProteinSolutions equipped with a microsampler temperature
control unit. The data obtained, were analyzed using Dynamics
software (ver 5.24.02).
HPLC
Soluble fraction generated from the acid/heat treatment was
analyzed on a 12.5 cm C18 reversed phase HPLC column (5 mm
particle size). The analysis was carried out with a 60 minutes linear
gradient starting with 90% solvent A (0.1% TFA in H2O) and
10% solvent B (0.1% TFA in acetonitrile) and ending with 100%
Human Amelogenin Production
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at 214 nm.
Mass spectroscopy
Amelogenin purified with the acid/heat treatment method was
diluted with 70% acetonitrile containing 0.1% TFA to a
concentration of ,10 pmol/ml. The MALDI sample was prepared
by adding 0.5 ml of 10 mg/ml sinapinic acid (dissolved in 50%
acetonitrile, 0.05% TFA) to the MALDI sample plate, and when
the matrix solution had dried 0.5 ml of the amelogenin solution
was added to the matrix spots. The dried sample was analyzed in
linear mode with an externally calibrated Applied Biosystems 4700
Proteomics Analyzer.
Enterokinase cleavage of amelogenin-PTH fusion
The fusion protein was purified in 3% HAc according to the
acid/heat treatment method described above. The cleavage was
carried out in 100 mM HAc pH 4.5, 1 mM CaCl2 at room
temperature using ,1 U/mg fusion of EKMax Enterokinase
(Invitrogen). The reaction was incubated for 24 hours and samples
were taken at different time points for analysis with SDS-PAGE.
Samples were also taken out where the amelogenin and
amelogenin-PTH were precipitated by adding 2.5 M NaOH until
pH was ,7, or by adding NaCl to a concentration of $150 mM.
The precipitate was removed by centrifugation and the superna-
tant containing PTH was analyzed by SDS-PAGE.
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